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Key Points
• Acalabrutinib preserves
Src family kinase activ-
ity and avoids dysfunc-
tional platelet thrombus
formation caused by
ibrutinib therapy.
• Platelet thrombus
formation is enhanced
by intermediate purity
factor VIII.
The Bruton tyrosine kinase (Btk) inhibitor ibrutinib induces platelet dysfunction and causes
increased risk of bleeding. Off-target inhibition of Tec is believed to contribute to platelet
dysfunction and other side effects of ibrutinib. The second-generation Btk inhibitor
acalabrutinib was developed with improved speciﬁcity for Btk over Tec. We investigated
platelet function in patients with non-Hodgkin lymphoma (NHL) receiving ibrutinib or
acalabrutinib by aggregometry and by measuring thrombus formation on collagen under
arterial shear. Both patient groups had similarly dysfunctional aggregation responses to
collagen and collagen-related peptide, and comparison with mechanistic experiments in
which platelets from healthy donors were treatedwith the Btk inhibitors suggested that both
drugs inhibit platelet Btk and Tec at physiological concentrations. Only ibrutinib caused
dysfunctional thrombus formation, whereas size and morphology of thrombi following
acalabrutinib treatment were of normal size and morphology. We found that ibrutinib but
not acalabrutinib inhibited Src family kinases, which have a critical role in platelet adhesion
to collagen that is likely to underpin unstable thrombus formation observed in ibrutinib
patients. We found that platelet function was enhanced by increasing levels of von
Willebrand factor (VWF) and factor VIII (FVIII) ex vivo by addition of intermediate purity
FVIII (Haemate P) to blood from patients, resulting in consistently larger thrombi. We
conclude that acalabrutinib avoids major platelet dysfunction associated with ibrutinib
therapy, and platelet function may be enhanced in patients with B-cell NHL by increasing
plasma VWF and FVIII.
Introduction
The Bruton tyrosine kinase (Btk) inhibitor ibrutinib was the first of a new class of drug for the treatment of
indolent non-Hodgkin lymphomas (NHLs).1 Treatment with ibrutinib has proven to be efficacious but is
associated with side effects, including increased risk of major bleeding.2 Bleeding associated with
ibrutinib is potentially explained by off-target inhibition of other kinases in addition to Btk; a study of
patients with X-linked agammaglobulinemia (XLA), who have Btk deficiency, reported no increased risk
of bleeding3 although genetic deficiency of Btk was found to increase time occlusion in a mouse model
of carotid artery injury.4 Furthermore, studies performed using genetically modified mice demonstrated
redundancy between Btk and Tec in platelet signaling because ablation of both kinases was required to
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render platelets fully insensitive to collagen in aggregation assays.5
The effect of simultaneous genetic ablation of Btk and Tec on
platelet adhesion under shear has not been explored in vivo or in
vitro. The off-target effects of ibrutinib on platelet function have added
complications to its use, such as risks associated with concurrent
treatment with anticoagulant or antiplatelet medication, which is
common among patients with chronic lymphocytic leukemia (CLL).6
Ibrutinib therapy is interrupted before surgery to reduce the risk of
bleeding, but prolonged dose interruption or dose reduction may
reduce efficacy and lead to a flare in symptoms.7 Acalabrutinib is a
second-generation Btk inhibitor and exhibits greater selectivity over
kinases that are important for platelet function such as Src family
kinases (SFKs) and Tec.8 No major bleeding events were reported
during a phase 2 trial of acalabrutinib for treatment of CLL,8 but it is
not yet clear if the selectivity of acalabrutinib is sufficient to fully avoid
the platelet dysfunction associated with ibrutinib.
Ibrutinib causes platelet dysfunction downstream of the GPVI
receptor, GPIb, and integrin aIIbb3.
9-11 Although XLA is not
associated with increased risk of bleeding, deficient expression or
function of GPVI,12-14 GPIb,15 or integrin aIIbb3
16 is associated with
bleeding phenotypes in mice or humans. The precise reason for the
discrepancy between bleeding risk in patients with XLA and
patients receiving ibrutinib has not been characterized, but is
thought to relate to off-target inhibition of Tec.8 However, ibrutinib
may also inhibit other important platelet kinases such as SFK that
phosphorylate several signaling molecules in the GPVI signaling
pathway.17 Btk and Tec are themselves dependent on SFK-mediated
tyrosine phosphorylation to become active.18,19 Inhibition of SFK is
known to cause hemostatic dysfunction because the Src inhibitor,
dasatinib, is associated with increased bleeding risk.20-22 Comparison
of ibrutinib and acalabrutinib therapy therefore represents an important
opportunity to characterize their relative effects and understand how
improved kinase specificity affects platelet dysfunction.
Thrombocytopenia is frequently associated with CLL and may be a
contributing factor to bleeding events in combination with drug-
induced platelet dysfunction.23,24 Treatment options for patients
that are at high risk of bleeding are currently limited and the clinical
efficacy of platelet transfusion has not been established.2 Evidence
that platelet transfusion may reverse platelet dysfunction caused by
ibrutinib is based on in vitro data11 with few studies investigating
this approach clinically.25 Furthermore, the benefit of platelet
transfusion during treatment with other antiplatelet medication is
Table 1. Patient information
Acalabrutinib 100 mg BD (n 5 8) Ibrutinib 480 mg OD (n 5 6) Btk inhibitor naı¨ve (n 5 5)
Age, median (range), y 68 (53-80) 68 (60-77) 78 (60-80)
Sex, n (%)
Female 2 (25) 3 (50) 3 (60)
Male 6 (75) 3 (50) 2 (40)
Diagnosis, n (%)
CLL 7 (87.5) 6 (100) 5 (100)
Mantle cell lymphoma 1 (12.5) — —
Laboratory parameters
Hemoglobin, median (range), g/L 139 (113-155) 131 (109-147) 140 (117-148)
Platelet count, median (range), 3109/L 148.5 (35-228) 114 (58-197) 118 (109-274)
Clinical details, n (%)
Concurrent antiplatelet drugs — — —
Concurrent anticoagulants 1 (13)* — —
Inherited bleeding disorders — — —
Duration of Btk inhibitor, median (range), mo 21.5 (19-32) 19 (2-39) —
Active bleeding at time of recruitment — — —
Bleeding on Btk inhibitor, n (%)†
None 3 (38) 5 (83) —
Grade 1 2 (25) 1 (17) —
Grade 2 3 (38) — —
Response to Btk inhibitor, n (%)‡
Complete remission 5 (63) 3 (50) —
Partial remission 3 (38) 3 (50) —
Stable or progressive disease — — —
BD, twice daily; OD, once daily.
*Dabigatran 150 mg twice daily.
†Common Terminology Criteria for Adverse Events grading scale.
‡International Workshop on Chronic Lymphocytic Leukemia criteria for chronic lymphocytic leukemia; positron emission tomography computed tomography criteria for mantle cell
lymphoma.
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Figure 1. Acalabrutinib and ibrutinib therapy cause dysfunctional GPVI-mediated platelet aggregation. PRP from patients receiving ibrutinib (Ibr; n 5 6),
acalabrutinib (Acal; n 5 7), healthy donors (n 5 9), or Btk inhibitor naı¨ve CLL patients (n 5 5) was loaded into 96-well microtiter plates containing lyophilized platelet agonists.
Plates were shaken for 5 minutes at 37°C and aggregation was measure by light transmission to give an end point measurement. (A) Scatter plot of EC50 values calculated from
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controversial and may lead to poorer outcomes.26 Investigating
alternatives to platelet transfusion to treat or prevent bleeding
during ibrutinib or acalabrutinib therapy is therefore a priority. One
alternative to platelet transfusion for bleeding patients, or those
undergoing surgery and at risk of bleeding from platelet dysfunction,
is administration of desmopressin,27-29 which stimulates secretion
of the contents of Weibel-Palade bodies and results in an acute
increase in plasma von Willebrand factor (VWF) and factor VIII
(FVIII) levels of two- to sixfold.30 Indeed, successful administration of
desmopressin to stop bleeding in patients suffering from thrombo-
cytopenia has also been reported.31 It may be possible to
administer desmopressin to treat bleeding or reduce bleeding risk
during treatment with Btk inhibitors, either as an alternative for or
adjunct to platelet transfusion. However, because ibrutinib inhibits
GPIb-mediated platelet function,11 it has remained unclear if this
approach might be beneficial.
Methods
Materials
Type I collagen was obtained from Nycomed (Munich, Germany) and
collagen-related peptide (CRP-XL) from Professor Richard Farndale
(University of Cambridge, Cambridge, United Kingdom). Adenosine
59-diphosphate (ADP), arachidonic acid, and U46619 were from
Sigma (Gillingham, United Kingdom), and TRAP-6 epinephrine was
from Labmedics (Salford, United Kingdom). Acalabrutinib, ibrutinib,
and dasatinib were from Selleckchem (Munich, Germany). Antiphos-
photyrosine antibody 4G10 was obtained from Millipore (Burlington,
MA). PKC substrate antibody and phospho-PLCg2 Y759 was from
New England Biolabs (Hitchin, United Kingdom). Phospho-Src 418
antibody and Fura-2 AM was from Life Technologies (Paisley, United
Kingdom). Phospho-Btk Y223, phospho-Lyn Y396, and phospho-b3
Y773 antibodies were from Abcam (Cambridge, United Kingdom).
Actin 11C antibody was from Santa Cruz Biotechnology (Heidelberg,
Germany). Greiner 96-well plates and DiOC6 were from Thermo
Fisher Scientific (Dartford, United Kingdom).
Patients. Trough blood samples were obtained from patients
withCLLormantle cell leukemia and receiving either ibrutinib (6 patients)
or acalabrutinib (8 patients; Table 1). Our control group comprised Bkt-
inhibitor naı¨ve CLL patients (5 patients). All patients provided informed
consent in accordance with the declaration of Helsinki. Ethics approval
for this study was covered under the Oxford Radcliffe Biobank research
tissue bank ethics, HTA License Number 12217, Oxfordshire C REC:
09/H0606/515, project approval code 17/A016.
Platelet preparation. Blood samples were obtained from
healthy donors that had given informed consent and using
procedures approved by the University of Reading Research Ethics
Committee or from patients and collected into vacutainers containing
3.8% (w/v) sodium citrate. Platelet-rich plasma (PRP) was prepared
by centrifuging whole blood at 100g for 20 minutes. Washed platelets
were prepared by adding acid citrate dextrose to PRP and
centrifuging at 350g for 20 minutes and resuspending the platelet
pellet at 43 108 cells/mL in Tyrode’s buffer as previously described.9
Plate-based aggregometry. For measurement of aggrega-
tion using PRP from patients or healthy donors, 96-well plates
(Greiner) containing the following freeze-dried platelet agonists at a
range of concentrations: ADP, CRP-XL, epinephrine, U46619,
collagen, and TRAP-6 were prepared in advance and stored in
vacuum-sealed bags for no more than 2 months. PRP isolated from
the blood of healthy donors or patients was loaded onto plates and
shaken at 1200 rpm for 5 minutes at 37°C using a plate shaker
(Quantifoil Instruments), as described by Lordkipanidze´ et al;
absorption of 405 nm light was measured using a Multiskan Ascent
354 Microplate Reader (LabSystems). Aggregation of washed
platelets was performed in 96-well plates as previously described.9
Thrombus formation under flow. Thrombus formation was
performed using blood from healthy donors using microfluidic flow
chips (Vena8, CellixLtd, Dublin, Ireland) coated with 100 mg/mL
type I collagen and measured in real time following incubation of
blood from healthy donors with ibrutinib, acalabrutinib, or vehicle for
10 minutes, or fixed with 10% formyl saline after 8 minutes of
perfusion at a shear rate of 1000 s21 and imaged at a later time.
Protein phosphorylation studies. Washed platelets at
4 3 108 cells per milliliter in the presence of inhibitors to prevent
aggregation (100 mM MRS2179, 1 mM cangrelor, 10 mM indometh-
acin, and 1 mM EGTA) were incubated with ibrutinib or acalabrutinib at
concentrations specified in individual figures or vehicle for 5 minutes at
37°C before addition of 1mg/mLCRP-XL. Samples were incubated for
3 minutes with stirring at 37°C using an aggregometer (Helena) before
addition of reducing Laemmli sample treatment buffer.
Phospho-Tec ELISA. Platelets were prepared and stimu-
lated as detailed previously but lysed in NP40 buffer (300 mMNaCl,
20 mM Tris base, 2 mM EGTA, 2 mM EDTA, 1 mM PMSF, 10 mg/mL
aprotinin, 10 mg/mL leupeptin, 0.7 mg/mL pepstatin A, 2 mM sodium
orthovanadate, 2% v/v NP-40; pH 7.3) and analyzed using a human
phosphotyrosine Tec enzyme-linked immunosorbent assay (ELISA
kit, RayBio). Absorption at 405 nm was measured using a NOVOstar
plate reader (BMG LabTech, Aylesbury, United Kingdom).
Ca21 measurement. The [Ca21]i assay was performed at
37°C using fura-2 loaded washed platelets in black 96-well plates
(Greiner). Dual excitation was measured using a Novostar
spectrofluorometer (BMG Labtech) previously described.9
Platelet adhesion to collagen. Washed platelets at
2 3 107 cells/mL were exposed to collagen (100 mg/mL)-coated,
96-well assay plates, and allowed to adhere for 45 minutes at 37°C.
Nonadherent platelets were washed off before, fixed with 10%
formyl saline for 10 minutes. The wells were then washed and
labeled with DiOC6. Fluorescence images of adherent platelets
were captured with the 203 objective lens of an ImageXpress Nano
high content imaging system and counted using CellReporterX-
press software (Molecular Devices, Winnersh, United Kingdom).
Figure 1. (continued) concentration response curves for ADP, U46619, epinephrine, TRAP-6, CRP-XL, and collagen. Each point represents the response of a patient receiving
acalabrutinib (red triangle) or ibrutinib (green square); healthy donor (gray circle) or Btk inhibitor naı¨ve CLL patient (white diamond). NR, patients that did not respond to an agonist
at the highest concentration tested. Concentration response curves for GPVI agonists (B) CRP-XL and (C) collagen; each point represents the mean % aggregation values 6
standard error of the mean (SEM). Significant differences relative to healthy donors were tested by 2-way ANOVA with the Turkey multiple comparisons test. Aggregation of washed
platelets from healthy donors pre-treated with a range of (D) acalabrutinib or (E) ibrutinib concentrations and then stimulated with 3 to 0.01 mg/mL CRP-XL.
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Figure 2. SFK activation and adhesion to collagen is spared by acalabrutinib but not ibrutinib. Washed human platelets from healthy donors were preincubated
with a range of (A) acalabrutinib or (B) ibrutinib and then stimulated with 1 mg/mL CRP-XL for 3 minutes at 37°C; tyrosine phosphorylation of Src (Y418) and Btk (Y223) were
measured by western blot using site-specific antibodies and total levels of Tec tyrosine phosphorylation were measure by ELISA. Points represent mean levels of tyrosine
phosphorylation relative to vehicle-treated controls 6 SEM. (C) Representative images of phosphoblots. Washed platelets treated with a range of acalabrutinib, ibrutinib, or
dasatinib concentrations and stimulated as previously and blotted for (D) tyrosine phosphorylation of Lyn (Y396) or (E) total phosphotyrosine using a site-specific antibody or
4G10, respectively. Points represent mean levels of tyrosine phosphorylation relative to vehicle-treated controls 6 SEM. (F) Aggregation 1 mg/ml CRP-XL stimulated of washed
platelets was performed in 96-well plates after treatment with a range of concentrations of acalabrutinib, ibrutinib, or dasatinib concentration response curves are mean platelet
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Fluorescence-activated cell sorting measurement of
fibrinogen binding and p-selectin exposure. Measurements of
fibrinogen binding and p-selectin exposure were performed
using washed platelets pretreated with inhibitors as described
in figure legends and stimulated with 1 mg/mL CRP in the
presence of fluorescein isothiocyanate–conjugated polyclonal
rabbit anti-fibrinogen antibody (Agilent Technologies LDA UK
Limited, Cheadle, United Kingdom) and PE-Cy5-conjugated
mouse anti-P-selectin (CD62P) antibody (BD, Berkshire, United
Kingdom), and then incubated for 20 minutes in the dark.
Platelets were then fixed by addition of filtered formyl saline
(0.2% formaldehyde in 0.15M NaCl) and median fluorescence
intensities were measured for 5000 platelets per sample on an
Accuri C6 Flow Cytometer (BD Biosciences, Berkshire, United
Kingdom).
Statistical methods. Statistical testing as described in
figure legends and the results section were performed using
GraphPad Prism Software (GraphPad, La Jolla, CA).
Results
Acalabrutinib and ibrutinib cause dysfunction of
GPVI-mediated platelet aggregation
Platelet aggregation to GPVI agonists has previously been shown to
be inhibited in blood samples taken from patients receiving
ibrutinib,10,11 but the effect of acalabrutinib on platelet function
has not been reported. Aggregation of PRP was used to
characterize platelet function of patients treated with ibrutinib or
acalabrutinib (Table 1). One patient receiving acalabrutinib was
excluded from this aspect of the study because of a low platelet
count (,50 3 109/L). The aggregation assay included ADP,
U46619, epinephrine, thrombin receptor activator peptide-6
(TRAP-6), CRP-XL, and collagen was adapted from the method
developed and validated by Lordkipanidze´ et al.32 We used a range
of agonist concentrations to enable comparison of patient
sensitivity to each agonist by estimation of the log half maximal
effective concentration (logEC50) by nonlinear regression analysis.
Results were compared with a group of healthy donors and Btk
inhibitor naı¨ve CLL patients (Figure 1A). Aggregation stimulated by
ADP, U46619, epinephrine, and TRAP-6 was not significantly
different in either patient group compared with healthy controls.
Responses to collagen were completely ablated in all patients tested
for both patient groups receiving Btk inhibitors, even at the highest
concentration of collagen (3mg/mL) (Figure 1A-B). Responses to the
GPVI receptor agonist CRP-XL were either less potent (ibrutinib,2
patients; acalabrutinib, 3 patients) or ablated (ibrutinib, 4 patients;
acalabrutinib, 4 patients) relative to responses of healthy controls
(logEC50 5 27.7M 6 0.30; Figure 1C) and Btk inhibitor naı¨ve
CLL patients (logEC50 5 27.3M 6 0.38). Experiments in which
CRP-XL was titrated against ibrutinib and acalabrutinib indicated
that 10mM acalabrutinib or 1mM ibrutinib was required to ablate
platelet aggregation of washed platelets from healthy donors
(Figure 1D-E).
Acalabrutinib is selective for SFK but not Tec
Both ibrutinib and acalabrutinib have been screened for activity
against a panel of kinases in cell-free, in vitro assays.8,33 However,
the estimated potency of the drugs in such assays does not
correspond closely with measurements performed in cell-based
assays. In addition to this, kinase regulation in the platelet is highly
complex and involves positive and negative feedback mechanisms.34
To elucidate the mechanistic differences between ibrutinib and
acalabrutinib that underpin differences in bleeding risk, we character-
ized the effects of the drugs on phosphorylation events downstream of
GPVI in platelets from healthy donors (Figure 2). Phosphorylation of
Btk Y223, the autophosphorylation site of Btk that correlates with its
kinase activity, was inhibited with equal potency by ibrutinib (log half
maximal inhibitory concentration [logIC50] 5 27.2M 6 0.30) and
acalabrutinib (logIC50527.1M6 0.21; Figure 2A-B). Inhibition of Tec
was harder to quantify because of the lack of site-specific phospho
antibodies, but total phosphotyrosine levels can be measured by
ELISA. Total Tec phosphotyrosine levels are likely to include the Tec
autophosphorylation site Y20635 as well as tyrosine residues phosphor-
ylated by other kinases such as SFK. We estimated that Tec was more
potently inhibited by ibrutinib (logIC50 5 26.4M) than by acalabrutinib
(logIC50525.5M; Figure 2A-B); however, the concentration-response
profiles of both ibrutinib and acalabrutinib were complex, involving both
positive and negative components and differential regulation of multiple
sites. Phosphorylation of the autophosphorylation site Y418 of Src
appeared to be potentiated by both drugs at lower concentrations.
However, at higher concentrations, ibrutinib also inhibited Src Y418
phosphorylation (logIC50 5 25.7M 6 0.18), whereas acalabrutinib did
not inhibit Src activity and actually potentiated activation even at high
concentrations (logEC50527.5M6 0.46; Figure 2A-B). Because our
data indicated that platelet Btk and Tec were likely to be inhibited
by physiological concentrations of both ibrutinib and acalabrutinib,
we further investigated inhibition of SFK by comparing both drugs to
the SFK inhibitor dasatinib. Phosphorylation of Lyn Y396 (Figure 2D)
was ablated by dasatinib (logIC50 5 27.1M 6 0.05) and ibrutinib
(logEC50 5 25.8M 6 0.08) but not acalabrutinib, which only
inhibited phosphorylation to 70% of vehicle-treated platelets at
the highest concentration tested (10 mM). Total phosphotyrosine
levels (Figure 2E) followed a similar pattern whereby dasatinib caused
near ablation of CRP-XL–evoked tyrosine phosphorylation
(logIC50 5 26.9M 6 0.24), whereas ibrutinib was less potent
(logIC50 5 25.1M 6 0.29) and acalabrutinib only inhibited partially
(71.7% of vehicle) at 10 mM.
Ibrutinib but not acalabrutinib potently inhibits
platelet adhesion to collagen
Aggregation of washed platelets evoked by 1 mg/mL CRP-XL was
completely ablated by acalabrutinib (logIC50525.3M6 0.06) and
with significantly greater potency by ibrutinib (logIC50 5 26.2M 6
0.28) and dasatinib (logIC50 5 26.6M 6 0.6; Figure 2F). We have
previously reported that discrepancies are present in the way that
ibrutinib inhibits platelet aggregation to immobilized collagen-
coated surfaces.9 Adhesion of platelets to collagen (Figure 2G) was
Figure 2. (continued) aggregation 6 SEM relative to vehicle-treated control. (G) Acalabrutinib, ibrutinib, or dasatinib-treated washed platelets from healthy donors were
allowed adhere to collagen-coated wells of a 96-well plate after 45 minutes at 37°C; graphs plot concentration response curves to mean numbers of adhered platelets 6 SEM
relative to vehicle treatment. (H) Representative images of phosphoblots for platelets treated with tyrosine kinase inhibitors.
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Figure 3. Acalabrutinib inhibits signal transduction downstream of GPVI with lower potency than ibrutinib. Washed human platelets from healthy donors were
preincubated with a range of acalabrutinib or ibrutinib concentrations and then stimulated with 1 mg/mL CRP-XL for 3 minutes at 37°C and phosphorylation of (A) PLCg2
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partially inhibited (;40% of vehicle) by ibrutinib (logIC50525.9M6
0.18) and dasatinib (logIC50 5 26.9M 6 0.09), which closely
matched their ability to inhibit Lyn activity. Acalabrutinib was a weak
inhibitor of adhesion to collagen and only reduced the number of
adhered platelet to 60% 6 9.4 of vehicle.
Acalabrutinib inhibits signaling downstream of GPVI
less potently than ibrutinib
To understand the consequences of the differences in kinase
specificity of the inhibitors, signaling events downstream of the
kinases were measured. We found that phosphorylation of the
Btk substrate, Y759 of PLCg2, was inhibited by both ibrutinib
(logIC50 5 26.7M 6 0.18) and acalabrutinib (logIC50 5 26.7 6
0.26; Figure 3B). However, acalabrutinib did not completely ablate
phosphorylation of PLCg2 Y759 even at the highest concentra-
tion of acalabrutinib tested. Phosphorylation of PKC substrates was
inhibited less potently by acalabrutinib (logIC50 5 26.2 M 6 0.19)
than by ibrutinib (logIC50 5 26.5 6 0.24, P , .05, Student t test;
Figure 3B). Acalabrutinib inhibited PKC activity by 52%6 4.5 relative
to vehicle, significantly less than ibrutinib, which inhibited by 72% 6
3.3 (P , .05, Student t test) at the highest concentration
tested. Release of Ca21 from intracellular stores into the cytosol is
stimulated downstream of PLCg2 and was also inhibited less
potently by acalabrutinib (logIC50 5 26.1M 6 0.08) than ibrutinib
(logIC50 5 26.7 6 0.07, P , .05, Student t test).
Acalabrutinib inhibits granule secretion and integrin
aIIbb3 activation less potently than ibrutinib
Secretion of a-granules was investigated by measuring exposure of
P-selectin on the platelet surface following stimulation with CRP-
XL. P-selectin exposure was more potently inhibited by ibrutinib
(logIC50 5 26.5M 6 0.04) than by acalabrutinib (logIC50 5 25.9M 6
0.11; Figure 4A). Binding of fluorescently labeled fibrinogen was
used as measure of integrin aIIbb3 activation following stimulation
with CRP-XL (Figure 4B). Fibrinogen binding was inhibited more
potently by ibrutinib (logIC50 5 26.5M 6 0.04) than by
acalabrutinib (logIC50 5 25.8M 6 0.07). Phosphorylation of the
integrin b3 subunit is a critical event in the initiation of integrin aIIbb3
outside-in signaling. Phosphorylation of b3 Y773 (corresponding to
Y747 in mouse) was potently inhibited by both ibrutinib (logIC50 5
26.7M 6 0.13) and acalabrutinib (logIC50 5 26.6M 6 0.11.
Figure 4C). Acalabrutinib appeared to be only a partial inhibitor of
b3 Y773 phosphorylation, because even at the highest concentra-
tion tested, a reduction to only 27% 6 2.5 relative to vehicle was
Figure 3. (continued) (Y759) and (B) PKC substrates (S/T) was measured by western blotting. (C) Representative western blot images for PLCg2 (Y759) and S/T
phosphorylated PKC substrates. (D) Cytosolic Ca21 following stimulation with 1 mg/mL CRP-XL was measured in fura-2 loaded platelets in real time for 5 minutes. Points
represent the mean response relative to vehicle 6 SEM. Representative [Ca21]i traces following incubation with (E) acalabrutinib or (F) ibrutinib.
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achieved, whereas ibrutinib caused inhibition to 6% 6 1.0 of
vehicle.
Acalabrutinib avoids dysfunctional thrombus
formation caused by ibrutinib
Given the differences in the effects of the drugs on adhesion to
collagen compared with GPVI-mediated aggregation, we com-
pared the effects of the drugs on platelet adhesion and thrombus
formation in collagen-coated flow chambers under arterial shear
conditions. After treating whole blood from healthy donors with
either 1 mM ibrutinib or acalabrutinib for 20 minutes, ibrutinib
caused reduced thrombus formation (1mM ibrutinib: 383AU64 0.1,
vehicle 585AU 6 67.6, P , .05, Student t test), whereas in
the presence of vehicle or acalabrutinib, thrombus formation was
not significantly different (Figure 5A-B). The most striking
difference between ibrutinib and acalabrutinib treatment was the
lack of stable, retracted thrombi after ibrutinib treatment
(Figure 5A). In the presence of vehicle or acalabrutinib, platelets
accumulated on collagen fibers while continuously contracting
into dense thrombi, whereas ibrutinib prevented retraction of
platelet aggregates, which consequently remained unstable,
appeared loose, and were prone to disaggregation (supplemental
Video 1). The effects of 1 mM ibrutinib and acalabrutinib on several
important signaling and functional measurements are summarized
in Figure 5B.
To test whether experiments performed using blood from
healthy donors matched the effects of drugs at therapeutic
concentrations, we performed measurements of thrombus
formation on collagen under arterial shear using blood samples
from healthy donors, Btk-inhibitor na ı¨ve patients, or patients
receiving ibrutinib or acalabrutinib (Table 1). Blood from
acalabrutinib patients formed morphologically normal thrombi
on collagen (Figure 6A), although heterogeneity in platelet
counts strongly influenced thrombus volume (Figure 6C).
Thrombus volume in acalabrutinib patients with platelet counts
.100 3 109/L (78 895 mm3 6 16 258) were not significantly
different to those of Btk-inhibitor naı¨ve patients (75 608 mm3 6
19 995, P . .05, Student t test). In contrast, thrombus volume
for ibrutinib patients was highly variable and did not correlate with
platelet count (Figure 6D). Images of thrombi measured in samples
from patients with platelet counts .150 3 109/L are presented in
Figure 6A. Samples from 2 of the ibrutinib patients exhibited very
pronounced dysfunction whereby platelets formed a loose covering
of the majority of the surface of the flow chamber without forming
stable thrombi (“large”; Figure 6A), whereas others formed small
thrombi (“small”; Figure 6A).
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Figure 5. Ibrutinib, but not acalabrutinib, causes thrombus
instability. Whole blood from healthy donors was incubated with
vehicle, 1 mM ibrutinib, and 1 mM acalabrutinib for 20 minutes and
flowed through collagen-coated microfluidic flow chambers at a
shear rate of 1000 s21 for 6 minutes. (A) Representative images of
thrombi formed under each of the conditions tested at 2-minute
intervals. (B) A summary of effects of 1 mM ibrutinib and 1 mM
acalabrutinib on thrombus formation on collagen and other platelet
signaling and functional measurements relative to vehicle-treated
control. Bars represent the mean 6 SD; P values were calculated
using multiple tests with Holm-Sidak correction for multiple
comparisons.
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Addition of Haemate P ex vivo to patients’ blood
improves platelet function
Thrombus formation assays using patients’ blood were per-
formed in the presence or absence of 2 units/mL of Haemate P.
Correlation of thrombus volume with platelet count was not
significant within the Btk-inhibitor naı¨ve patient group because
platelet counts were all .100 3 109/L and thrombus volume
was fairly uniform. The correlation was significant in patients
treated with acalabrutinib in the presence and absence of
Haemate P (Figure 6B), but not in patients treated with ibrutinib
(Figure 6C), despite half of the patients having platelet counts
,100 3 109/L, which strongly influences thrombus volume.
Addition of Haemate P significantly increased thrombus volume
in healthy donors and patients treated with acalabrutinib or
ibrutinib (P , .05, 2-way analysis of variance (ANOVA) with
repeated measures and the Sidak multiple comparisons test;
Figure 7).
Discussion
Ibrutinib has proven to be an effective treatment of low-grade NHL
but is associated with an increased risk of bleeding, whereas the
effects of the second-generation Btk inhibitor, acalabrutinib, on
platelet signaling and function have not been studied in detail.
Ibrutinib has been shown to inhibit platelet aggregation evoked by
GPVI receptor agonists,9-11 but the effects of acalabrutinib therapy
on platelet aggregation have not been reported. We found that
aggregation evoked by collagen and CRP-XL was either partially
or completely inhibited in all patients receiving ibrutinib or
acalabrutinib (Figure 1). Peak plasma concentrations of ibrutinib
and acalabrutinib have been estimated at approximately 300 nM
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and 1.7 mM, respectively, in vivo,8,36 but our characterization of the
concentration-response profile of both drugs in vitro (Figure 1D-E)
indicated that a concentration of acalabrutinib corresponding to
3 to 10 mM would be required to achieve the level of inhibition of
CRP-XL evoked signaling observed in patients. For this reason, we
concluded that the apparent potency of acalabrutinib when
measured by treatment of platelets in vitro was lower than that
observed in patients. We hypothesize that accumulation of the
drugs may occur in platelets because of their irreversible mode of
actions and lack of protein turnover in platelets.
Although we found that ibrutinib and acalabrutinib inhibited Btk
activity with similar potency, our study of kinase activation
downstream of GPVI identified differences in the way the drugs
affected SFK and Tec (Figure 2). Although the specificity of both
kinases has been characterized in vitro8,33 and ibrutinib has been
shown to inhibit SFK and Btk in platelets,9,11 a comprehensive
comparison of ibrutinib and acalabrutinib has not previously been
reported. We found that activation of Src was potentiated by
acalabrutinib and that the concentration-response profile mirrored
the inhibition curve for Btk Y223, suggesting that Btk mediates
negative feedback regulation on SFK when active. At intermediate
concentrations of acalabrutinib, Tec activation was similarly in-
creased, likely as a direct result of the potentiation of Src, which is
known to regulate activation of Tec family kinases.37 Ibrutinib
caused potentiation over a narrow concentration range because
direct inhibition of Tec and Src occurred at intermediate and high
concentrations.
Our in vitro experiments indicate that only concentrations of
acalabrutinib that inhibit Tec activation (3-10 mM; Figure 2) are
able to ablate platelet aggregation evoked by CRP-XL (Figure 1D).
Therefore, our observation that CRP-XL–evoked aggregation was
strongly inhibited during acalabrutinib therapy (Figure 1) sug-
gested that therapeutic doses of acalabrutinib must inhibit Tec,
despite the improvement in selectivity relative to ibrutinib.
However, we went on to demonstrate both in vitro and with blood
samples from patients receiving ibrutinib or acalabrutinib that only
ibrutinib causes severe platelet dysfunction measured by throm-
bus formation on collagen under conditions of arterial shear
(Figure 7). Taken together, these data suggest that Tec family
kinase activity is required for CRP-XL–mediated platelet aggre-
gation but is redundant for adhesion and thrombus formation on
collagen, which is instead dependent on SFK. We believe that this
important distinction underlies the absence of severe platelet
dysfunction in patients receiving acalabrutinib and that greater
selectivity for Tec family kinases over SKF is likely to be the cause
of this difference. Our observation that acalabrutinib did not inhibit
SFK, and in fact caused potentiation of SFK activation (Figure 2),
may be an important factor in compensating for the loss of Btk
kinase activity.
We found that GPVI-mediated platelet aggregation and signaling
still occurs when Btk activity is absent, because several functional
and signaling events occur at near vehicle-treated levels following
treatment with 1 mM acalabrutinib, a concentration that ablates Btk
activity (Figure 5). Our data suggest that this may be a direct result
of potentiation of signaling through Tec and SFK, which enable Tec
to mediate normal levels Ca21 signaling, PKC and integrin aIIbb3
activation, and a-granule secretion despite being expressed at
approximately eightfold lower levels than Btk in platelets.38 This
potentiation mechanism has not previously been reported and may
also explain why bleeding risk is not increased in Btk-deficient XLA
patients.3
We have previously reported that ibrutinib inhibits integrin aIIbb3
outside-in signaling, clot retraction, and thrombus stability, attributing
this observation to loss of Btk-mediated PLCg2 activation downstream
of integrin aIIbb3.
9 However, in the present study, we found that
downstream of GPVI, phosphorylation of b3 Y773, which is the first
step in outside-in signaling, was potently inhibited by ibrutinib and
acalabrutinib and therefore is likely mediated, at least partially, by Btk
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Figure 7. Platelet function is improved by ex vivo addition of
Haemate P. Comparison of the volume of thrombi formed in the
presence or absence of Haemate P added ex vivo to blood from healthy
donors (n 5 6), Btk inhibitor naı¨ve CLL patients (n 5 5), or patients
receiving ibrutinib (n 5 6) or acalabrutinib (n 5 8, as described in
Figure 7). Two-way ANOVA with repeated measures and Sidak multiple
comparisons test.
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(Figure 4). Inhibition of b3 Y773 phosphorylation occurs at concentra-
tions of acalabrutinib that allow almost normal levels of [Ca21]i
signaling, fibrinogen binding, and aggregation, indicating that this is a
direct consequence of Btk inhibition and not reduced integrin
activation. Additionally, the inhibition profile of b3 Y773 matches that
of PLCg2 Y759, a known Btk substrate.39 However, we found that b3
Y773 phosphorylation was not sensitive to ibrutinib or acalabrutinib
downstream of GPCR stimulation (unpublished observation). Mice
with dual mutation of the corresponding tyrosine residue Y747 and
also Y759 in the cytoplasmic tail of b3 are prone to rebleeding in tail
bleeding experiments 16; therefore, inhibition of integrin aIIbb3 signaling
may contribute to the bleeding side effects caused by ibrutinib.
In healthy donors, only ibrutinib caused a reduction in platelet
adhesion to collagen (Figure 5) and inhibited retraction of thrombi
(supplemental Video 1). In samples from some patients, ibrutinib
caused a striking lack of clot retraction, resulting in the formation of
a layer of loosely packed platelets, whereas in others the size of the
thrombi appeared reduced relative to Btk-inhibitor naı¨ve patients
with similar platelet counts (Figure 6). The reason for the variability
between ibrutinib patients was unclear but may relate to differences
in drug concentration or patient physiology; however, thrombus
volume did not seem to correlate with sensitivity to CRP-XL
measured by aggregometry. Treatment with acalabrutinib did not
affect thrombus formation or retraction, however, and platelet count
was the major determinant of thrombus volume in these patients
(Figure 6).
We studied ex vivo addition of Haemate P to blood from patients
with CLL or mantle cell leukemia receiving ibrutinib or acalabrutinib
to approximate the increase in levels of VWF and FVIII that might be
achieved following administration of desmopressin to a patient that
expresses functional VWF, and measured thrombus formation on
collagen (Figure 7). We found that Haemate P increased platelet
adhesion to collagen in all patients, regardless of treatment type or
platelet count. This finding suggests that agents that increase
plasma levels of VWF may improve primary hemostasis in CLL
patients at increased risk of bleeding either from thrombocytopenia
or drug-induced platelet dysfunction. Platelet transfusion has been
investigated as a means to overcome platelet dysfunction during
ibrutinib therapy in patients at risk of bleeding.11,25 However, the
safety and efficacy of platelet transfusion to reduce bleeding risk in
other contexts is controversial and investigation of alternatives is
ongoing.31 Desmopressin has been proven effective at improving
primary hemostasis in a number of contexts, including platelet
dysfunction27,30 and may act both via increasing VWF levels in
plasma as well as directly affecting platelets.40 Although ibrutinib
has been shown to inhibit adhesion to VWF-coated flow
chambers,11 our experiments demonstrate that VWF still contrib-
utes to and enhances thrombus formation on collagen; therefore,
our data suggest that this could still be a potentially efficacious
treatment of patients treated with ibrutinib. Investigation of platelet
function in patients that are currently experiencing bleeding during
ibrutinib therapy as well as evaluation to improve platelet function
could offer further insights into Btk-inhibitor induced platelet
dysfunction and potential treatments. Safety improvements of
successive generations of Btk inhibitors combined with a better
understanding of treatment options for bleeding may further
improve outcomes patients with NHL.
In conclusion, we found that Btk activity is redundant in the context
of GPVI-mediated platelet aggregation if Tec is functional, but is lost
if both tyrosine kinases are simultaneously inhibited. However, Btk
and Tec are redundant for platelet adhesion and thrombus
formation on collagen under flow, whereas SFK play a critical role
and are inhibited by ibrutinib but not acalabrutinib. Loss of SFK
function and inhibition of stable thrombus formation is likely to
contribute to bleeding risk in ibrutinib treated patients, but we found
evidence that platelet function could be improved by agents that
increase plasma VWF levels.
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